Brokerages Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $6.07

Key Points

• Vor Biopharma Inc. (NYSE:VOR) has received a consensus recommendation of "Moderate Buy" from nine research firms, with four hold ratings and five buy ratings.
• The average 1-year price target among analysts is $6.07, reflecting optimism about the company’s growth.
• Institutional investors hold 97.29% of Vor Biopharma's stock, indicating significant confidence from large stakeholders.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $6.0667.

A number of research analysts have weighed in on the stock. Wedbush reaffirmed an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Citizens Jmp cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 9th. Baird R W cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Jones Trading cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target on shares of Vor Biopharma in a research report on Thursday, August 14th.

Insider Activity at Vor Biopharma

In other news, major shareholder Reprogrammed Interchange Llc sold 806,351 shares of the business's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $2.01, for a total transaction of $1,620,765.51. Following the transaction, the insider directly owned 36,884,567 shares of the company's stock, valued at approximately $74,137,979.67. The trade was a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 2,089,534 shares of company stock worth $4,262,465 over the last 90 days. Insiders own 0.45% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Northern Trust Corp lifted its position in shares of Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares in the last quarter. RA Capital Management L.P. lifted its position in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Lynx1 Capital Management LP acquired a new position in shares of Vor Biopharma during the fourth quarter worth $707,000. Money Concepts Capital Corp lifted its position in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Vor Biopharma during the fourth quarter worth $80,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Price Performance

VOR stock traded down $0.04 during midday trading on Friday, reaching $1.97. 3,646,453 shares of the company's stock traded hands, compared to its average volume of 7,788,396. The company has a market capitalization of $249.57 million, a P/E ratio of -1.19 and a beta of 2.06. Vor Biopharma has a fifty-two week low of $0.13 and a fifty-two week high of $3.29. The business has a 50-day moving average price of $1.96 and a two-hundred day moving average price of $1.09.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.